The KOP Drug Platform is designed to treat cancer by targeting, blocking and silencing particular cancer genes with minimal side effects and preventing recurrences.
We anticipate the KOP-101 P Drug to successfully target many more tumor types but if necessary can streamline more drugs as stated below.
Mr. Brian William Karam has practiced law in Ottawa, Canada since 1973. From 1995 to 2015, the focus of his legal practice was large multi-family mortgage work, a portion of which involved difficult to structure social housing initiatives. Until the mid-1980’s he worked with First Nation artists and craft-persons. Thereafter he served for 5 years as President of CODE, a Canadian NGO, working to enhance literacy and education in the third world. He also developed the first fibre-to-the-door subdivision in the world, with formal live/work zoning that involved housing construction beginning 2005. He holds the USA and Canadian Patent on infrastructure for any Smart Building. He is also involved in the Hotel/Restaurant business and a longtime member of the charitable Dewaan Foundation. His philanthropy has focused on local hospitals and assisting immigrants to Canada to establish family operated businesses. Such latter efforts were formally recognized by a plaque presented to him by the Embassy of Lebanon. He has among other honours, received The Queen’s Diamond Jubilee Medal and the Sovereign’s Medal for Volunteerism and the United Way Community Builder Award.
Scientific Advisory Board Member
KOP Therapeutics
Eric Mathur currently serves Chief Executive Officer of Diomics and is focused on development and commercialization of a novel polymer with broad applications in diagnostics, forensics, nutraceutical and drug delivery marketplaces. His expertise and knowledge traverses’ genome sciences, molecular biology, environmental microbiology, plant-microbe interactions, metagenomics, enzyme & drug discovery, plant domestication and applied biotechnology.
Mathur’s career spans over 40 years in basic and applied biotechnology with focus on translational science. Eric entered the San Diego biotechnology arena early, in 1983 as founder of Stratagene, where he discovered and commercialized Pfu DNA polymerase, which is still a mainstay enzyme used in the PCR industry. After a nine years’ tenure, Mathur was recruited to become the first employee of Diversa Corporation, which later achieved the largest biotech IPO of the time, raising $200MM in 2001. At Diversa, Eric managed a large scientific team and multiple corporate collaborations with industrial partners including Syngenta, Dow Chemical and BASF. Following 14 years with Diversa, Mathur was recruited to start Craig Venter’s company, Synthetic Genomics where he led research efforts in microbial enhanced hydrocarbon recovery sponsored by BP; he also spearheaded the genome sequencing and annotation the oil palm genome for Genting Berhad; and established a platform for plant growth promoting bacteria which led to the spinout, Agradis and subsequent Monsanto acquisition.
Eric’s interests then turned to plant genomics and crop domestication; he worked as Chief Science Officer for several companies including Yulex Corporation and SG Biofuels, GreenKiss NY and Cultivation Technologies Inc., and most recently Tilt Holdings, where he applied modern genomic tools and plant molecular breeding methods to accelerate plant productivity. His work culminated in dramatic yield improvements in these two sustainable crops, Guayule for natural rubber production and Jatropha for biodiesel. In addition, Mathur’s team has made significant advances in Cannabis & Hemp and continues plant improvement activities with a number of organizations.
Eric Mathur is an internationally recognized speaker who authored over 50 peer-reviewed publications and is named inventor on 100+ issued patents. Eric’s passion lies in leveraging genome-based technologies to develop nutrient dense foods and therapeutic medicinals; Mathur is also an ardent supporter of sustainable agricultural and does his part to help secure global food & energy security, while minimizing the impact on our fragile environment.
Chief Business Development Officer & Director
KOP Therapeutics
Mr. Inwentash is a director and VP of Investments at ThreeD Capital, where he focuses on identifying, researching, and meeting with early stage companies in various disruptive industries. He is also a registered Dealer Representative and has a successful track record of raising capital in industries such as mining, battery recycling, organic food, high performance computing, biotechnology and blockchain. Mr. Inwentash has significant capital markets experience; he is an advisor and board member of several private and publicly listed companies.
KOP Therapeutics
Advisory Board Member
KOP Therapeutics
Advisory Board Member
Head of Research
Director
New York University School of Law
KOP Therapeutics
Executive Chairman & Director
KOP Therapeutics
President, CEO & Chairman
KOP Therapeutics
Mr. Gajdics has been a licensed investment professional, recognized by the Canadian Securities Commission since 1982, registered as a stockbroker with the BC Securities Commission and the IIROC, Investment Industry Regulatory Organization of Canada. Licensed to manage investments for individual clients in 1982 at Yorkton Securities, Mr. Gajdics retired in 1998 and established himself as a specialist in corporate governance, project finance, mergers, and acquisitions. As an Entrepreneur and investor with over 35 years in the business of raising equity for start ups and mid tier companies, Mr. Gajdics specialized in the structuring of early-stage companies as well as identifying the specific financial instruments best suited for each venture with a special interest in the resource sector.
Currently, as President and Chief Executive Officer of KOP Therapeutics, Mr. Gajdics entered into discussions with Thomas Jefferson University and The Sydney Kimmel Cancer Center. Working closely with Dr. Mathew Thakur and Dr. Eric Wickstrom (lead investigators and creators of the new and novel Technology) which lead to the acquisition of the Worldwide Exclusive license in early 2019 for the Newly discovered Cancer Therapy Platformed, designed to Kill Cancer Cells with little or no side effects.
Mr. Gajdics is responsible for the commercialization of the Technology, raising the required seed capital, negotiating the research agreements and instrumental in the patent strategy and execution in partnership with Thomas Jefferson University. Mr. Gajdics is responsible for guiding KOP Therapeutics, and its future vision to give Cancer survivors a fighting chance to live normal lives, free of Cancer.